Kalaris Therapeutics (KLRS) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
KLRS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kalaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.17 |
| 52 Week High | US$11.88 |
| 52 Week Low | US$2.14 |
| Beta | 0 |
| 1 Month Change | -17.91% |
| 3 Month Change | -58.13% |
| 1 Year Change | 36.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.64% |
Recent News & Updates
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth
Summary Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS’s lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26. KLRS stock's valuation is driven by TH103’s clinical potential, with an enterprise value of ~$119M and significant upside tied to trial catalysts. Read the full article on Seeking AlphaKalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent updates
Shareholder Returns
| KLRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.9% | -1.7% | -2.7% |
| 1Y | 36.3% | 24.3% | 22.5% |
Return vs Industry: KLRS exceeded the US Biotechs industry which returned 26.1% over the past year.
Return vs Market: KLRS exceeded the US Market which returned 22.7% over the past year.
Price Volatility
| KLRS volatility | |
|---|---|
| KLRS Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KLRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KLRS's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 20 | Andrew Oxtoby | kalaristx.com |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
Kalaris Therapeutics, Inc. Fundamentals Summary
| KLRS fundamental statistics | |
|---|---|
| Market cap | US$102.09m |
| Earnings (TTM) | -US$44.10m |
| Revenue (TTM) | n/a |
Is KLRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLRS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.10m |
| Earnings | -US$44.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KLRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 09:17 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kalaris Therapeutics, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Marc Goodman | Leerink Partners LLC |